{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:46:44Z","timestamp":1772506004859,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Zandelisib, a selective, potent PI3K\u03b4 inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zandelisib for relapsed or refractory follicular lymphoma or marginal zone lymphoma. Sixty\u2010one patients received zandelisib orally at 60\u2009mg daily continuously in the first two 28\u2010day\u2009cycles, followed by intermittent dosing on Days 1\u20137 following each cycle until progressive disease or unacceptable toxicity. Objective and complete response rates were 75.4% (95% confidence interval [CI], 62.7%\u201385.5%) and 24.6% (95% CI, 14.5%\u201337.3%) respectively. Median time to response was 58\u2009days; 70.5% (43\/61) of patients achieved their first response by Week 8. At least one Grade\u2009\u2265\u20093 treatment\u2010emergent adverse event (TEAE) occurred in 55.7% of patients: transaminase elevation (8.2%); cutaneous reactions (3.3%); and diarrhoea, enterocolitis and lung infection (1.6% each), defined as adverse events of special interest. The discontinuation rate due to any TEAE was 14.8%. No zandelisib\u2010related death occurred. Zandelisib showed favourable efficacy and tolerability in Japanese patients with relapsed or refractory indolent non\u2010Hodgkin B\u2010cell lymphoma. This unique dosing schedule may maintain efficacy while mitigating the safety issues observed with other PI3K\u03b4 inhibitors (ClinicalTrials.gov number, NCT04533581).<\/jats:p>","DOI":"10.1111\/bjh.19994","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:39:27Z","timestamp":1736383167000},"page":"541-550","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A phase <scp>II<\/scp> study of zandelisib in patients with relapsed or refractory indolent non\u2010Hodgkin lymphoma: <scp>ME<\/scp>\u2010401\u2010<scp>K02<\/scp> study"],"prefix":"10.1111","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-0656","authenticated-orcid":false,"given":"Wataru","family":"Munakata","sequence":"first","affiliation":[{"name":"Department of Hematology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kumode","sequence":"additional","affiliation":[{"name":"Hematology and Rheumatology Kindai University Faculty of Medicine  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[{"name":"Division of Laboratory and Transfusion Medicine Hokkaido University Hospital  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Hematology Tohoku University Hospital  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsu","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Oncology Tokyo Metropolitan Komagome Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Oncology and Hematology Chiba Cancer Center  Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[{"name":"Hematology NHO Kumamoto Medical Center  Kumamoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohmei","family":"Kubo","sequence":"additional","affiliation":[{"name":"Hematology Aomori Prefectural Central Hospital  Aomori Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Anjo Kosei Hospital  Anjo Aichi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Hematology and Oncology JRC AMC Nagoya Daini Hospital  Nagoya Aichi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9742-8470","authenticated-orcid":false,"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Cancer Institute Hospital, JFCR  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-6656","authenticated-orcid":false,"given":"Michiko","family":"Ichii","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Osaka University Graduate School of Medicine  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyoko","family":"Hanaya","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kuriki","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Seike","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co., Ltd  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"Department of Hematology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Nursing Tohoku Fukushi University  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03432-2"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04126-y"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00400"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30155-8"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1170394"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-315705"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275305"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352492"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S309171"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943354"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00333-3"},{"issue":"8","key":"e_1_2_12_15_1","article-title":"The PI3K\u03b4 inhibitor zandelisib on intermittent dosing in relapsed\/refractory follicular lymphoma: results from a global phase 2 study","volume":"8","author":"Zelenetz AD","year":"2024","journal-title":"Hema"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03450-5"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4648"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00915"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00746-8"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.09.006"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00934.x"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2000.00611.x"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2926"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010648"},{"key":"e_1_2_12_28_1","unstructured":"European Medicines Agency.Assessment report on provisional measures: Zydelig[Internet].2016. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/referral\/zydelig\u2010article\u201020\u2010procedure\u2010assessment\u2010report\u2010provisional\u2010measures_en.pdf"},{"key":"e_1_2_12_29_1","unstructured":"European Medicines Agency.Assessment report: Zydelig[Internet].2016. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/zydelig\u2010h\u2010c\u2010003843\u2010a20\u20101439\u20100023\u2010epar\u2010assessment\u2010report\u2010article\u201020_en.pdf"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:14:58Z","timestamp":1747739698000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/bjh.19994"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19994","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"2024-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}